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Abstract
Background: Occurrence of tumor relapse is frequent in patients with carcinoma of the papilla of Vater despite the absence
of residual tumor detectable at primary surgery. Therefore it has to be assumed that current tumor staging procedures fail to
identify minimal amounts of tumor cells disseminated to secondary organs, which might be precursors of subsequent
metastatic relapse. The aim of the study was to assess the frequency and prognostic impact of minimal tumor cell spread in
lymph nodes classified as ‘tumor-free’ in routine histopathologic evaluation. Materials and methods: A total of 41 ‘tumor-
free’ lymph nodes from 23 patients with adenocarcinoma of the papilla of Vater who underwent curative tumor resection
(R0) were examined by immunohistochemistry with the monoclonal anti-EpCAM antibody Ber-EP4 for minimal
disseminated tumor cells. Results: Twelve (29.3%) of the 41 ‘tumor-free’ lymph nodes obtained from 9 (39.1%) of the
23 patients displayed EpCAM-positive cells. KaplanMeier survival analysis revealed that patients with EpCAM-positive
cells in lymph showed a clearly reduced relapse-free and overall survival compared with patients without such cells.
However, these differences were not statistically significant (p/ 0.13 for relapse-free survival, p/ 0.11 for overall survival).
Discussion: Immunohistochemical assessment may refine the staging of resected lymph nodes in patients with carcinoma of
the papilla of Vater. However, the presence of minimal disseminated tumor cells in lymph nodes had no significant impact
on the prognosis in these patients.
Key Words: micrometastasis, lymph nodes, carcinoma of the papilla of Vater, minimal residual disease, immuno-
histochemistry
Introduction
Adenocarcinomas of the papilla of Vater are highly
aggressive malignancies with an unchanged poor
prognosis. Although postoperative mortality has de-
clined and resection rates have improved consider-
ably, the reported 5-year survival rates after complete
tumor resection (R0) still range between 45% and
65% [1]. Early metastatic relapse after the complete
resection of an apparently localized primary tumor
indicates an occult tumor cell dissemination or
micrometastatic disease, which cannot be detected
by current staging procedures. Therefore, more sen-
sitive immunohistochemical and nucleic acid-based
assays have been developed that are based on the
detection of epithelial cell or tumor-associated mar-
kers and are able to detect disseminated tumor cells in
lymph nodes classified as ‘tumor-free’ by conventional
histopathologic examination [216]. However,
although an increasing number of published studies
indicate that immunohistochemically detected mini-
mal tumor cell deposits in ‘tumor-free’ lymph nodes
appeared to be strong and independent predictors of
tumor relapse in several carcinoma entities
[5,6,11,14,1620], little is known about the prognos-
tic value of these cells in patients with carcinoma of
the papilla of Vater.
In order to identify patients with a high risk for
tumor relapse we applied an immunohistochemical
assay to assess the frequency and prognostic value of
immunohistochemically detectable tumor cells in
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lymph nodes in 23 patients with completely resected
(R0) adenocarcinoma of the papilla of Vater.
Materials and methods
Patients
This study was approved by the ethics committee of
the chamber of physicians in Hamburg. Informed
consent was obtained from all the patients before their
inclusion in the study. Lymph nodes were prospec-
tively collected from 23 consecutive patients with
adenocarcinoma of the papilla of Vater without overt
metastases (M0) who underwent radical pancreato-
duodenectomy with tumor-free resection margins
(R0) at the University Hospital Hamburg during
March 1993 and April 2002. In each patient recon-
struction was performed with a pancreatojejunostomy
according to Whipple-Kausch [21]. None of the 23
study patients received a neoadjuvant treatment.
The clinical and histopathological data of the 23
patients analyzed in this study are summarized in
Table I.
Patient survival was determined from the time of
primary surgery to the time of death or last follow-up.
The median postoperative observation time was
20 months (range 6118 months).
Lymph node preparation and immunohistochemical
detection of tumor cells
During the systematic lymphadenectomy the surgeon
randomly collected lymph nodes that were macro-
scopically unsuspicious and divided them into two
parts, as described previously [17]. One part of each
lymph node was embedded in paraffin for routine
histopathological examination, whereas the other
part was snap-frozen in liquid nitrogen and stored
at /808C for immunohistochemical analysis. If a
lymph node was ‘positive’ on routine histopathology,
it was excluded from the immunohistochemical ana-
lysis. The remaining nodes, which were ‘negative’ on
routine histopathology, were further analyzed immu-
nohistochemically. From each of these nodes cryostat
sections of 68 mm thickness were cut at three
different levels. Two consecutive samples obtained at
each level were stained immunohistochemically with
the monoclonal antibody (mAb) Ber-EP4 (IgG1;
Dako, Hamburg Germany and Carpinteria, CA,
USA) for the presence of disseminated tumor cells.
This mAb detects the epithelial cell adhesion mole-
cule (EpCAM), also known as 17-1A or EPG40,
which is frequently expressed by epithelial cells and
epithelial-derived tumors [9,22]. We and other groups
previously demonstrated that immunohistochemical
analysis with anti-EpCAM antibodies is a sensitive
and specific method for detecting disseminated tumor
cells in lymph nodes in a variety of carcinoma entities
[5,6,9,14,17,23,24]. Visualization of antibody bind-
ing was performed by the alkaline phosphatase-anti-
alkaline phosphatase (APAAP) technique [14].
Sections of normal colonic mucosa served as
positive controls, and isotype-matched, irrelevant
murine monoclonal antibodies (MOPC-21; Sigma,
Germany) were used for negative controls. The
immunostained slides were evaluated in a blinded
fashion by two observers working independently.
Statistical analysis
Associations between categorical parameters were
assessed via Fisher’s exact test. The KaplanMeier
method was used to analyze overall survival and
relapse-free survival times. Log-rank tests were per-
formed for comparison purposes. Differences between
Table I. Characteristics of patients and tumors.
Variable No. (%) of patients No. (%) of patients with EpCAM/cells in LN p value
All patients 23 9 (39.1)
Male 12 (52.2) 3 (25)
Female 11 (47.8) 6 (54.5) 0.2
Median age 66 years (4783)
B/60 years 7 (30.4) 3 (42.9)
]/60 years 16 (69.6) 6 (37.5) 0.6
Primary tumor
pT1 3 (13) 1 (33.3)
pT2 8 (34.8) 4 (50)
pT3 11 (47.8) 4 (36.4)
pT4 1 (4.3) 0 0.8
Lymph nodes
pN0 14 (60.9) 5 (28.6)
pN1 9 (39.1) 4 (44.4) 0.5
Tumor grade
G1 3 (13) 0
G2 12 (52.2) 7 (58.3)
G3 8 (34.8) 2 (25) 0.1
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groups were considered significant if the p values were
B/0.05 for a two-tailed test (software SPSS 10.0,
SPSS Inc. 1999).
Results
The clinical data of the analyzed patients are sum-
marized in Table I. Routine histopathologic examina-
tion of the resected lymph nodes revealed lymph node
metastases in 23 (8.5%) of 270 resected lymph nodes
from 9 (39.1%) of the 23 patients. Of 247 lymph
nodes judged as ‘tumor-free’ by routine histopathol-
ogy, 41 lymph nodes (mean 1.8 lymph nodes per
patient) were further analyzed by immunohistochem-
istry. This analysis revealed EpCAM-positive cells in
12 (29.3%) of 41 lymph nodes from 9 (39.1%) of the
23 patients (Table I). Five (28.6%) of these patients
were classified as pN0. These cells presented as
isolated tumor cells or small tumor cell clusters
located in the sinuses or the lymphoid interstitium.
There was no correlation between the presence of
EpCAM-positive cells in lymph nodes and clinico-
pathologic parameters, such as primary tumor stage
(pT), lymph node stage (pN), or grading (G) (Table I).
All 23 patients were available for KaplanMeier
survival analysis. Five (55.9%) of nine patients with
EpCAM-positive cells in lymph nodes developed
tumor relapse within a median time of 14 months
and 6 (66.7%) of them died in the course of their
disease within a median time of 12 months, compared
with 4 (28.6%) and 5 (35.7) of 14 patients without
such cells within a median relapse-free survival of
/15 months and a median overall survival of
/20 months (Table III, Figures 1 and 2). However,
these differences were not statistically significant for
both the relapse-free survival (p/ 0.13) and overall
survival (p/0.11). The prognostic value of the other
established clinicopathologic parameters is summar-
ized in Table III.
Discussion
Despite improvements in surgical treatment, the
prognosis of patients with adenocarcinoma of the
papilla of Vater has not changed remarkably over
the last decades and is known to be correlated with the
presence of lymph node metastasis [1]. Since sensitive
immunohistochemical or nucleic acid-based ap-
proaches have been introduced for tumor cell detec-
tion, several investigators have demonstrated the
frequent presence of minimal tumor cell deposits in
lymph nodes previously judged as ‘tumor-free’ on
routine histopathologic examination in many types of
malignant tumors [220,25,26]. However, the clin-
ical and biological significance of such immunohisto-
chemically detected cells is still controversially
discussed. Some authors have reported a lack of
Table II. Prognostic value of EpCAM-positive cells in lymph nodes.
Survival Patients without EpCAM/cells in LN Patients with EpCAM/cells in LN p value*
Relapse-free
All patients’ events (%) 5/14 (35.7) 6/9 (66.7)
Months$ /15 12 0.13
Overall
All patients’ events (%) 4/14 (28.6) 5/9 (55.9)






























Figure 1. Relapse-free survival of patients with and without
EpCAM-positive cells in lymph nodes.





Age (B/60 vs ]/60 years) 0.2
pT34 vs pT12 0.08
pN1 vs pN0 0.03
Grade III vs grade III 0.1
Overall survival
Sex 0.08
Age (B/60 vs ]/60 years) 0.1
pT34 vs pT12 0.2
pN1 vs pN0 0.1
Grade III vs grade III 0.3
*Log-rank test.
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significant impact of these cells on prognosis
[12,13,25], whereas others described a strong effect
on postoperative outcome [46,9,16,17,19,20,26].
However, according to a recent Medline search
(June 2006) there are no data published regarding
the frequency and prognostic value of immunohisto-
chemically detected tumor cells in lymph nodes in
patients with adenocarcinoma of the papilla of Vater.
We therefore analyzed a total of 41 ‘tumor-free’ lymph
nodes from 23 patients with completely resected (R0)
cancer of the papilla of Vater and found disseminated
tumor cells in 9 (39.1%) of these patients. Five
(55.6%) of these patients displaying disseminated
tumor cells in lymph nodes were judged as pN0 on
routine histopathology. Although patients with dis-
seminated tumor cells in lymph showed a clearly
reduced relapse-free and overall survival compared
with patients without such cells, these differences
were not of statistical significance.
Most studies examining pathohistologically ‘tumor-
free’ lymph nodes in carcinoma patients by immuno-
histochemistry have applied antibodies against a
broad spectrum of cytokeratins (CKs) (e.g. mAb
AE1/AE3) [24,16,19,20,25,26]. However, de-
scribed irregular CK expression (e.g. CK18) in
normal lymphatic reticulum cells [27] can lead to
false positive results. Therefore we used a monoclonal
antibody against EpCAM, which is more specific for
tumor cell detection in lymph nodes
[5,6,9,14,17,23,24] since it is not expressed in
lymphatic tissues [14,22]. Applying this approach,
we and other groups were able to demonstrate that
detection of EpCAM-positive cells in ‘tumor-free’
lymph nodes was of independent prognostic signifi-
cance for a worse postoperative prognosis in patients
with carcinoma of the pancreas [6,24], esophagus
[5,17], and lung [9,14]. The lack of significance of
disseminated tumor cells in lymph nodes in the
present study can be mainly attributed to the low
number of patients analyzed. Therefore, further
studies with larger numbers of patients are needed
to resolve the question of the prognostic value of
minimal disseminated tumor cells in lymph nodes in
patients with carcinoma of the papilla of Vater. If
these analyses reveal a significant impact of these cells,
immunohistochemical assessment of lymph nodes
could be used to refine the staging system for cancer
of the papilla of Vater and help to identify patients at a
high risk of tumor recurrence, which cannot be cured
by surgery alone. The detection of the earliest
manifestations of tumor cell dissemination is an
extremely promising approach, which might enable
us to identify suitable candidates for adjuvant treat-
ment strategies, for instance with humanized thera-
peutic anti-EpCAM antibodies.
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